Feasibility Study of New Method of Diagnostic and Prediction of Painful CIPN
Stopped early · Not applicable
Conditions studied: Burning Pain, Impaired Balance, Malignant Ovarian Neoplasm, Numbness, Peripheral Neuropathy, Pain, Acute, Tingling
In brief
This clinical trial studies how well Diode laser fiber type Selective Stimulator (DLss) works in predicting pain development in patients with ovarian cancer who are receiving chemotherapy. Stimulating of the pain nerve fibers in the skin with laser light stimulation may help to predict whether a patient will develop painful peripheral neuropathy, correlate with the severity of neuropathy during and after chemotherapy treatment, and may help to explain the mechanisms of chemotherapy-induced neuropathic pain (CIPN).
Key facts
- Study ID
- NCT03206216
- Run by
- Stanford University
- People needed
- 1
- Starts
- 2017-08-04
- Expected to finish
- 2017-10-30
- Last updated by the study team
- 2018-12-19
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Pathologically-proven ovarian cancer, or cancer of mullerian origin, that was or will be treated with a 1st-line taxane plus a platinum-based chemotherapy regimen.
- GROUP A (painful neuropathy group): Subjective symptoms of painful peripheral neuropathy (burning, stabbing, throbbing, painful tingling, aching in the fingers and/or toes) that is greater than or equal to 10 on a scale of 0 to 100 in the neuropathic pain questionnaire
- GROUP B (painless neuropathy group): Subjective symptoms of painless neuropathy (loss of sensation, worsening balance, strange sensation in fingers and/or toes) or no complaints related to neuropathy.
- Life expectancy of 6 months
- Ability to understand the study protocol, participate in testing, and the willingness to sign a written informed consent document.
You may not qualify if…
- Received prior chemotherapy for ovarian cancer or cancer of mullerian origin other than 1st-line treatment with a taxane + platinum based regimen.
- No concurrent investigational drugs.
- Received investigational drugs suspected to cause peripheral neuropathy.
- History of B12 deficiency
- History of neuropathy or numbness/tingling suspicious for neuropathy, prior to the first dose of chemotherapy for ovarian cancer
- Prior treatment for other cancers that included drugs known to cause neuropathy (including but are not limited to vinca-alkaloids, platinums, taxanes, bortizomib).
- Known peripheral vascular disease
- Chronic daily headache or headache for more than 14 days of the month
- Pain rated 50 or higher on a scale of 0 to 100, with 0 = no pain at all and 100 = worst pain imaginable.
- Pregnant or nursing
- HIV-positive
- Do not speak or read English
Where it is running
- Stanford University, School of Medicine — Palo Alto, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.